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Through the phase 3 International Randomized Study of Interferon vs. STI571 (IRIS) trial, 
imatinib emerged as the standard treatment for chronic myeloid leukemia (CML) and has 
successfully prolonged the duration of both the chronic phase (CP) and the disease-free 
state. The majority of newly diagnosed patients treated for CP-CML achieve a complete 
cytogenetic response (CCyR), and over time, most of these eventually achieve major 
molecular responses (MMRs) and even complete molecular responses (CMRs). In 
ongoing phase 3 randomized trials of second-generation tyrosine kinase inhibitors (TKIs), 
nilotinib and dasatinib have been found to have superior efficacies in helping achieve 
cytogenetic and molecular responses, including MMRs and CMRs. However, only the 
MMR rate was significantly higher in bosutinib compared with the imatinib control, but 
not in CCyR rate. Current reports of imatinib discontinuation suggested that achieving 
CMR is an important prerequisite for CML to be cured. Recent data from the STIM (Stop 
Imatinib) trial showed that imatinib can be successfully discontinued in patients who 
achieve a certain level of CMR. Standardized real-time quantitative reverse transcriptase- 
polymerase chain reaction (RQ-PCR) assays have been available in routine clinical 
practice, and efforts are being focused on achieving higher sensitivity and optimizing the 
time of imatinib discontinuation. Although very few patients are cured by administration 
of only Bcr-Abl TKIs, including imatinib and second-generation TKIs, current advances 
may eventually make this possible. This report summarizes the detailed clinical data 
obtained in the DASISION, ENESTnd, and BELA studies and discusses high-sensitivity 
detection methods and future therapeutic strategies.
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LONG-TERM MOLECULAR RESPONSE OF IMATINIB: 
DATA FROM IRIS AND HAMMERSMITH AND 
SEOUL ST. MARY’S HOSPITAL
1. Incidence of molecular responses
In the IRIS trial, previously untreated CP-CML patients 
(N=1,106) were randomly assigned to receive either imatinib 
(N=553) or interferon (IFN)-α plus cytarabine (N=553). 
During the sixth year of study treatment, the cumulative 
best CCyR rate was 82%. The estimated event-free survival 
at 6 years was 83%, and the estimated progression-free sur-
vival (PFS) rate was 93% [1]. The IRIS study showed that 
during the median follow-up of 19 months, 21% and 4% 
of patients in the imatinib group had achieved MMR and 
CMR, respectively [2]. In a substudy of 53 imatinib-treated 
IRIS patients, the probability of Bcr-Abl being undetectable 
increased considerably from 36 to 81 months of first-line 
imatinib treatment (7% vs. 52%). Bcr-Abl became un-
detectable in 18 of 53 patients, and none of whom lost MMR 
after a median follow-up of 33 months. In contrast, MMR 
was lost in 6 of 22 (27%) patients with sustained detectable 
Bcr-Abl [3]. In a study conducted in the Hammersmith hospi-
tal on 204 CP-CML patients receiving imatinib as first-line 
therapy, at 5 years, 159 patients (77%) had achieved a CCyR 
(median time, 7 months; range, 3-55.4 months), 80 (39%) 
had achieved an MMR (median time, 15.7 months; range, 
2-73 months), and 10 (5%) had achieved a CMR (median 
time, 30.7 months; range, 12-67.4 months). The cumulative 
incidences of CCyR and MMR were 82.7% and 50.1%, 
respectively. Of the 80 patients who achieved an MMR, 
the response was sustained in 90% [4]. In our current study 
with 363 new CP patients, the cumulative incidences of 
CCyR, MMR, and CMR
4.5 at 5 years increased to 92%, 52%, 
and 11%, respectively. At 7 years, the cumulative incidences 
of CCyR, MMR, and CMR
4.5 were 94%, 60%, and 14% Korean J Hematol 2011;46:169-74.
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Table 1. Relationship between early molecular response and patient outcomes.
Bcr-Abl 1/ABL1 
transcript ratio
Probability of outcome according to transcript ratio at specified time points, %
MMR (Bcr-Abl 1/ABL1＜0.05%) Event
a)
3 months 6 months 12 months 3 months 6 months 12 months
≤0.1% 100 96 97 4 1 3
＞0.1% to 1% 84 69 61 3 7 2
＞1% to 10% 53 44 20 11 9 8
＞10% 33 15 7 13 23 50
a)Event was defined as loss of complete hematologic response, loss of major cytogenetic response, or an increasing white cell count (defined 
as a doubling of the count to more than 20×10
9/L on 2 occasions at least 1 month apart), progression to accelerated phase/blast crisis, or death
from any cause during imatinib treatment.
Abbreviation: MMR, major molecular response.
respectively. In addition, when compared to the group re-
ceiving less than 400 mg/d, the 400 mg/d group demonstrated 
a better 6-year cumulative incidence of MMR (82% vs. 66%, 
respectively,  P=0.014) and CMR
4.5 (38% vs. 13%, re-
spectively,  P=0.0042) (unpublished data). Therefore, re-
sponse rates might be directly correlated with treatment 
intensity.
2. Significance of molecular responses
Several studies have reported different clinical im-
plications of MMRs at specific time points in long-term sur-
vival outcomes. The IRIS study proved that MMRs at 12 
and 18 months can predict significantly better PFS [2]. 
Moreover, the achievement of an MMR by 18 months of 
therapy was proposed to be the goal of therapy [5]. However, 
other studies have reported that such differences may not 
be clinically relevant and that only the achievement of CCyR 
was significant in order to predict survival [4, 6]. Early ach-
ievement of molecular responses correlates with achieve-
ment of MMRs and a reduction in the number of events. 
As summarized in Table 1, the prognostic significance of 
early molecular responses is clear; patients with a Bcr-Abl 
ratio of 1% or less at 3 months had very low event rates, 
with a median follow-up of 53 months [7]. The CMR rate 
gradually increased with continuing imatinib treatment, and 
CMR was more common in patients who achieved an MMR 
early.
MOLECULAR RESPONSES IN ENESTnd, DASISION, 
AND BELA TRIALS
1. Frontline second-generation TKI studies; ENESTnd, 
DASISION, and BELA
Investigations are currently underway to determine the 
efficacy and safety of second-generation Bcr-Abl TKIs in 
the treatment of newly diagnosed CP-CML, including the 
multicenter, phase 3, randomized clinical trials “Evaluating 
Nilotinib Efficacy and Safety in Clinical Trials-Newly 
Diagnosed Patients” (ENESTnd) [8] and “Dasatinib versus 
Imatinib Study in Treatment-Naïve CML Patients” 
(DASISION) [9]. These studies have shown that Nilotinib 
and dasatinib have superior efficacies than imatinib. 
Bosutinib, currently an investigational agent not yet ap-
proved for CML treatment, is also being studied in the 
“Bosutinib versus Imatinib in Patients with Chronic Phase 
Chronic Myeloid Leukemia” (BELA) trial [10]. In the 
ENESTnd study, 846 patients were randomly assigned to 
receive 300 mg nilotinib twice daily (N=282), 400 mg niloti-
nib twice daily (N=281), and 400 mg imatinib once daily 
(QD; N=283). In the DASISION trial, 519 patients with newly 
diagnosed CP-CML were randomized to receive first-line 
treatment with either 100 mg dasatinib QD (N=259) or 400 
mg imatinib QD (N=260). In the BELA study, 502 patients 
with newly diagnosed CP-CML were randomized to receive 
first-line treatment with either 500 mg bosutinib QD (N=250) 
or 400 mg imatinib QD (N=252). The ENESTnd, DASISION, 
and BELA trials had different study designs, primary end-
points, and definitions. Therefore, direct comparison of the 
results is not possible. Presently, 24 months of data from 
the ENESTnd and DASISION studies, and 18 months of 
data from the BELA study are available, and significantly 
higher rates of MMR and CMR
4.5 were observed with niloti-
nib, dasatinib, and bosutinib than with imatinib [10-12]. 
2. Comparison of molecular responses between second- 
generation TKIs and Imatinib
By 24 months into the ENESTnd study, significantly more 
patients had achieved an MMR with nilotinib than with 
imatinib: 71% of patients receiving nilotinib at 300 mg twice 
daily, 67% of patients receiving nilotinib at 400 mg twice 
daily, and 44% of patients receiving imatinib showed an 
MMR (P＜0.0001 for both comparisons). In addition, sig-
nificantly more patients in the nilotinib groups achieved 
a CMR
4.5 at any time than those in the imatinib group (26% 
of patients receiving nilotinib at 300 mg twice daily, 21% 
of patients receiving nilotinib at 400 mg twice daily, and 
10% of patients receiving imatinib achieved a CMR) [11]. 
By 24 months into the DASISON study, the rate of MMRs 
was superior for dasatinib vs. imatinib (64% vs. 46%, re-
spectively), and the CMR
4.5 rate was also higher for dasatinib 
vs. imatinib (17% vs. 8%, respectively) [12]. From 12 to Korean J Hematol 2011;46:169-74.
The path to cure CML 171
Table 2. Results of imatinib discontinuation in different clinical 
settings.
Response at time of treatment 
discontinuation
Patients with molecular and/or 
cytogenetic relapse, %
CCyR
13 100%
MMR
14 100%
MMR, CCyR, MCyR
15 100%
CMR for ≥2 years on imatinib
16 ＞50%
Abbreviations: CCyR, complete cytogenetic response; MMR, 
major molecular response; CMR, complete molecular response.
24 months, dasatinib also continued to show better efficacy 
than imatinib for the treatment of CML. The MMR rate 
at 18 months in the BELA study was higher with bosutinib 
(46%; 95% CI, 39-52%) than with imatinib (38%; 95% CI, 
32-44%), and 9% of patients achieved a CMR
4.5 with bosuti-
nib, compared with 4% who achieved a CMR with imatinib 
[10]. Overall, patients achieved their first molecular re-
sponses faster and deeper with all 3 of these second-gen-
eration TKIs than with imatinib.
STUDIES ON DISCONTINUATION OF TKIs
1. Discontinuation of imatinib
Although imatinib therapy is effective and currently con-
sidered a front-line therapy in patients with CML, it is still 
unclear whether intermittent imatinib therapy can be safely 
employed in particular situations such as pregnancy and 
serious adverse events. Thus far, in studies on the dis-
continuation of TKI therapy, 100% of patients with less 
than a CMR have relapsed (Table 2) [13-15]. Therefore, 
it may be necessary for patients to achieve a CMR before 
physicians consider potentially discontinuing TKI therapy 
[16]. In our study, the majority of patients maintained their 
best achieved response after resuming imatinib treatment 
[13]. Therefore, although imatinib cannot be discontinued 
completely, transient interruption can be considered for the 
treatment of patients with CML in particular situations such 
as serious or life-threatening concomitant diseases, preg-
nancy, or major surgery.
In the STIM study, patients with more than 2 years of 
d o c u m e n t e d  C M R s  w h i l e  o n  imatinib therapy attempted 
therapy discontinuation. A total of 69 patients were followed 
up for more than 12 months. Nineteen of 34 patients (55.9%) 
who received prior INF-α therapy relapsed, and 23 of 35 
patients (65.7%) who received imatinib as first-line therapy 
relapsed. The Sokal scores showed that 17 of 35 patients 
(48.6%), 15 of 23 patients (65.2%), and 7 of 8 patients (87.5%) 
who relapsed were at low, intermediate, or high risk, 
respectively. In addition, 27 of 51 patients (52.9%) who 
received more than 50 months of imatinib treatment re-
lapsed, compared with 15 of 18 patients (83.3%) who received 
less than 50 months of imatinib therapy [16]. Typically, 
patients who enrolled in the STIM trial had deeper and 
longer molecular responses while on imatinib therapy than 
patients in other studies, and therefore, discontinuation of 
therapy should not be attempted outside of a controlled 
clinical trial with frequent monitoring.
2. Discontinuation of second-generation TKIs
In a study on discontinuation of dasatinib or nilotinib 
in 17 adult patients who had achieved a CMR
4.5 [17], of 
t h e 12 pat ien ts with  a minimu m f o llo w-u p perio d o f  6 mo nt hs 
(median, 12; range, 7-18), 11 had imatinib intolerance and 
1 had imatinib resistance, and 30% (4/12) of patients lost 
the MMR by 6 months of discontinuation. The MMR was 
rapidly regained upon re-introduction of early second-gen-
eration TKIs. Treatment was also restarted in 1 patient in 
whom there was no MMR loss but who showed CMR loss 
on 2 consecutive assessments. Seven patients remained off 
therapy at the last follow-up after a median of 11 months 
(range, 7-18), with either a stable CMR or weakly detectable 
Bcr-Abl transcripts on one or more occasions. Although a 
longer follow-up with more patients will be required, the 
study provided a basis for further studies on discontinuation 
of second-generation TKIs. In addition, since current front-
line second-generation TKI data from the DASISION and 
ENESTnd studies are showing that the probability of persis-
tent CMR by 36 months of follow-up remains higher with 
dasatinib and nilotinib than with imatinib, more patients 
receiving second-generation TKI therapies may be safely 
discontinued in the future.
HIGH-SENSITIVITY PCR TECHNOLOGY
1. Definition of molecular responses by conventional RQ- 
PCR
The principal means of monitoring a patient’s response 
to therapy is to assess their hematologic, cytogenetic, and 
molecular responses as well as their long-term outcomes 
[5, 18]. Since therapies for CML have improved, patients 
have been able to achieve responses at the molecular level. 
Therefore, more sensitive measurements are necessary to 
detect minimal residual disease (MRD). Real-time quantita-
tive polymerase chain reaction (RQ-PCR) assessment can 
detect deeper levels of response, up to a 5-log reduction 
[6]. Generally, molecular response is a measure of the level 
of Bcr-Abl transcripts as determined by RQ-PCR and is de-
scribed as a ratio of Bcr-Abl to a housekeeping gene (such 
as ABL, BCR, or GUS). An MMR is achieved when a patient 
reaches a 3-log reduction in Bcr-Abl transcripts from a base-
line value defined in the IRIS trial [2, 19]. Since inter-labo-
ratory variation in the methods of conducting RQ-PCR makes 
comparison of data between laboratories difficult, the inter-
national scale (IS) has been developed to allow for cross-labo-
ratory comparison of PCR results [20]. The IS is defined 
by 2 values: (1) a baseline value (i.e., pretreatment with 
imatinib) of the Bcr-Abl/ABL ratio, which was defined based 
on an analysis of baseline levels in patients from the IRIS Korean J Hematol 2011;46:169-74.
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trial (100%), and (2) a 3-log reduction thereof, or a reduction 
to 0.1% or less, which is defined as an MMR [2]. To convert 
the PCR results obtained in a laboratory to the IS, the results 
are modified using a laboratory-specific conversion factor 
that is calculated by comparing patient samples against a 
reference method [20]. Deeper molecular responses are now 
defined as achieving a CMR
4.0 of more than 4.0-log reduction 
(Bcr-Abl
IS≤0.01%), a CMR
4.5 of more than 4.5-log reduction 
(Bcr-Abl
IS≤0.005%), and a CMR
5.0 of more than 5-log reduc-
tion in Bcr-Abl transcripts (Bcr-Abl
IS≤0.001%) [21, 22]. In 
the STIM trial, the selection criteria for candidates was based 
on the duration of imatinib therapy and the duration of 
PCR negativity prior to discontinuation, and conventional 
RQ-PCR was employed to measure PCR negativity. However, 
the fact that the absolute number of residual leukemia clones 
could not be measured under the detection limits of conven-
tional RQ-PCR might have resulted in relapse in more than 
half of the patients. This indicates that conclusions cannot 
be drawn about whether a patient could safely discontinue 
therapy solely based on conventional RQ-PCR. The absence 
of Bcr-Abl transcripts in conventional RQ-PCR is sometimes 
unreliable since some patients, despite being PCR-negative, 
relapse and PCR negativity may be maintained after imatinib 
discontinuation [23, 24]. It might be necessary to develop 
more sensitive assays that can provide a more reliable estima-
tion of the therapeutic response of the patient, and thus 
allow further classification of patients who may discontinue 
imatinib without the risk of relapse. With the advent of 
more potent TKIs, more sensitive assays would also be able 
to extend the period of measurable disease by several years 
in most patients with CML. This will help in further assess-
ment of the kinetics of Bcr-Abl under the detection limit 
of conventional RQ-PCR, whereas conventional RQ-PCR 
will become less useful for many patients who show dramatic 
responses to therapy and in whom Bcr-Abl transcripts in 
undetectable.
2. High-sensitivity PCR technologies
With the emergence of increasingly efficacious therapies 
leading up to imatinib, the majority of patients with Ph+ 
CML were able to achieve deeper levels of response. 
Increasingly sophisticated and sensitive methods of disease 
detection have been developed in parallel to facilitate the 
detection of these deeper patient responses. To demonstrate 
the feasibility of more sensitive approaches, several methods 
have been developed using DNA-based PCR [25] and 
RNA-based PCR assays [26]. Replicated PCR (rRQ-PCR), 
DNA-based PCR, and RNA-based digital PCR (dPCR) assays 
have successfully detected Bcr-Abl transcripts that were pre-
viously not detectable by conventional RQ-PCR, and these 
data show the potential feasibility of high-sensitivity PCR 
approaches for molecular monitoring and their clinical rele-
vance in future strategies for drug discontinuation by allow-
ing further characterization of patients who achieve PCR 
negativity in conventional RQ-PCR assays. In our study, 
rRQ-PCR allowed for a 2-log improvement in detection sen-
sitivity, and therefore, use of this method might increase 
the chances of detecting very low Bcr-Abl transcript levels, 
the probability of which increases with the number of repeti-
tions [26]. In addition to rRQ-PCR, the concept of partition-
ing in dPCR, in conjunction with a pre-amplification step, 
also successfully achieved a 2-3-log improvement in de-
tection sensitivity. Although implementation of a pre-ampli-
fication step prior to conventional RQ-PCR also increased 
the sensitivity to a level comparable to that of rRQ-PCR, 
significant variations in the detection of Bcr-Abl copy num-
bers were evident in samples with low levels of Bcr-Abl 
transcripts in replicate experiments. Therefore, although the 
sensitivity was improved by pre-amplification in conven-
tional RQ-PCR, dPCR would be an attractive alternative 
tool for accurate detection of low levels of MRD with high 
sensitivity. In the future, more strict PCR sensitivity criteria 
using highly sensitive technologies should be employed to 
accurately assess Bcr-Abl transcript levels prior to dis-
continuation and then to consider whether discontinuation 
of TKI therapy may be safe.
THERAPEUTIC STRATEGIES FOR POTENTIAL CURE
1. Definition of curability
In practical terms, some criteria have defined curability 
as (1) sustained molecular response, (2) successful dis-
continuation of TKI therapy, (3) 100% CML-related survival, 
and (4) quality of life (QoL) comparable to that of age-match-
ed population. Although considerable progress has recently 
been made in CML therapy, a true cure for the disease 
can only be obtained by our present therapeutic means in 
a rather small minority of patients. Since leukemia stem 
cells (LSCs) in CML are insensitive to imatinib treatment 
[27], and the self-renewal ability of LSCs can result in 
re-emergence of disease even after a long period of RQ-PCR 
negativity, sustained undetectable MRD is obtained only 
in a minority of CML patients treated with TKIs. It still 
is not clear whether these patients are definitively cured 
of leukemia, or whether LSCs persist in their bone marrow. 
The relationship between LSC persistence and the potential 
risk of disease relapse for patients with long-term un-
detectable MRD warrants further investigation [28].
2. New therapeutic targets for curing CML
Although the molecular differences in Bcr-Abl expression 
between hematopoietic stem cells (HSCs) and LSCs are still 
unclear, the best means of identifying stem cell targets in 
CML is to fully understand CML-initiating genetic changes. 
Recently, several new targets or drugs have been found to 
inhibit LSCs in cultured human CD34+ CML cells or in 
mouse models of Bcr-Abl-induced CML, including an Alox5 
pathway inhibitor, Hsp90 inhibitors, omacetaxine, a hedge-
hog inhibitor, and the farnesyl transferase inhibitor 
BMS-214662. To obtain the ultimate goal of a cure for CML, 
2 strategies have been tested. One important strategy has 
been to inhibit target genes such as those encoding hedgehog 
[29], Wnt/β-catenin [30], and Bim-1 [31] in order to function-Korean J Hematol 2011;46:169-74.
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Fig. 1. Role of normal stem cells and leukemia stem cells.
ally regulate both normal stem cells and LSCs. Another ap-
proach has been the specific targeting of LSC-related genes, 
but not those of normal stem cells, for developing new anti-
cancer therapies in the future (Fig. 1) [32].
Currently, several drugs targeting LSCs have been 
reported. The hedgehog pathway is active in many tissues, 
where it plays a critical role in hematopoiesis and is activated 
in Ph+ CML stem cells [33]. The smoothened antagonist, 
LDE225, is currently in phase 1 clinical trial for the treatment 
of Ph+ CML and other cancers. Janus kinase 2 inhibition 
may inhibit stem cells [34], and INF may stimulate quiescent 
LSCs to proliferate, making them susceptible to TKI therapy 
[35]. Residual disease may be the result of the presence 
of LSCs, which can act as a reservoir of disease that cannot 
be eradicated by TKI therapy alone [27, 36]. Relapses can 
occur even in patients who have undergone potentially cura-
tive stem cell transplants, suggesting that residual disease 
may be present even in patients with prolonged CMRs [37, 
38]. Therefore, the inhibition of LSCs may be a crucial step 
in curing CML. Several trials utilizing INF maintenance 
therapies and/or combination therapies with potent TKIs 
and/or LSC-targeting agents are ongoing. Future CML man-
agement might include earlier use of these agents to help 
more patients achieve CMRs and may be a means of curing 
CML.
CONCLUSION
During the past decade, considerable progress has been 
made in understanding the biology of CML, which has raised 
hopes that this disease may be curable. Early intensification 
using combination therapies with more potent TKI- and 
LSC-targeted agents is required for the development of more 
sensitive PCR assays. The achievement of deeper responses, 
measured only by highly sensitive assays, will establish a 
necessary first step toward potentially discontinuing drug 
therapy.
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